arrow
Back
B

Brad Rosbrook

pfizer usa

31H-index
149Paper Count
7.9KCitation Count
Published Papers 38
Publication Date
Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial
err2026-05-01
err6
PREAI
errShore, Neal D.; Gleave, Martin; De Giorgi, Ugo; Rannikko, Antti; Pieczonka, Christopher M.; Sridharan, Swetha; Brasso, Klaus; Woo, Henry H.; Gomez Caamano, Antonio; Saranchuk, Jeff W.; Nordquist, Luke T.; Ferreira, Ubirajara; Tang, Yiyun; Rosbrook, Brad; Haas, Gabriel P.; Rosales, Matt; Zohren, Fabian; Tarazi, Jamal; Freedland, Stephen J.
errShare
errSave
Clinical Outcomes of Enzalutamide in Metastatic Hormone-sensitive Prostate Cancer in Patients Aged <75 and ≥75 Years: ARCHES Post Hoc Analysis
err2024-08-01
err1
errOAAI
errGomez-Veiga, Francisco; Szmulewitz, Russell Z.; Holzbeierlein, Jeffrey; Azad, Arun A.; Iguchi, Taro; Villers, Arnauld; Alcaraz, Antonio; Alekseev, Boris; Shore, Neal D.; Rosbrook, Brad; Zohren, Fabian; Ma, Jie; Haas, Gabriel P.; Stenzl, Arnulf; Armstrong, Andrew J.
errShare
errSave
Enzalutamide (enza) monotherapy for the treatment (tx) of prostate cancer with high-risk biochemical recurrence (BCR): EMBARK secondary endpoints
err2023-10-01
err1
errOAAI
errDe Giorgi, U. F. F.; Freedland, S. J.; Gleave, M. E.; Tutrone, R.; Bailen, J. L.; Roos, E.; Kliment, J.; Marx, G. M.; Karsh, L. I.; Ramirez-Backhaus, M.; Uchio, E.; Supiot, S.; Tang, Y.; Rosbrook, B.; Haas, G. P.; Rosales, M.; Zohren, F.; Shore, N. D.
errShare
errSave
Treatment (tx) of high-risk biochemically recurrent prostate cancer with enzalutamide (enza) in combination with leuprolide acetate (LA): Secondary endpoints from EMBARK
err2023-10-01
err2
errOAAI
errFreedland, S. J.; Gleave, M. E.; De Giorgi, U. F. F.; Rannikko, A.; Pieczonka, C.; Sridharan, S.; Brasso, K.; Woo, H.; Caamano, A. Gomez; Saranchuk, J.; Nordquist, L. T.; Ferreira, U.; Tang, Y.; Rosbrook, B.; Haas, G. P.; Rosales, M.; Zohren, F.; Shore, N. D.
errShare
errSave
A Plain Language Summary looking at how long side effects last after treatment with axitinib is stopped in people with advanced renal cell carcinoma
err2023-08-01
err2
errOAAI
errRini, Brian I.; Atkins, Michael B.; Choueiri, Toni K.; Teresi, Rosemary E.; Rosbrook, Brad; Thakur, Maghull; Hutson, Thomas E.
errShare
errSave
The Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: A Post Hoc Analysis of ARCHES
err2023-08-01
err6
errOAAI
errArmstrong, Andrew J.; Iguchi, Taro; Azad, Arun A.; Villers, Arnauld; Alekseev, Boris; Petrylak, Daniel P.; Szmulewitz, Russell Z.; Alcaraz, Antonio; Shore, Neal D.; Holzbeierlein, Jeffrey; Gomez-Veiga, Francisco; Rosbrook, Brad; Zohren, Fabian; Haas, Gabriel P.; Gourgiotti, Georgia; El-Chaar, Nader; Stenzl, Arnulf
errShare
errSave
Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC)
err2021-09-01
err29
errOAAI
errArmstrong, A. J.; Iguchi, T.; Azad, A. A.; Szmulewitz, R. Z.; Holzbeierlein, J.; Villers, A.; Alcaraz, A.; Alekseev, B. Y.; Shore, N. D.; Petrylak, D. P.; Rosbrook, B.; Zohren, F.; Yamada, S.; Haas, G. P.; Stenzl, A.
errShare
errSave
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
err2021-08-21
err17
PREAI
errAzad, Arun A.; Armstrong, Andrew J.; Alcaraz, Antonio; Szmulewitz, Russell Z.; Petrylak, Daniel P.; Holzbeierlein, Jeffrey; Villers, Arnauld; Alekseev, Boris; Iguchi, Taro; Shore, Neal D.; Gomez-Veiga, Francisco; Rosbrook, Brad; Lee, Ho-Jin; Haas, Gabriel P.; Stenzl, Arnulf
errShare
errSave
ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
err2021-06-01
err8
errOAAI
errQuinn, D., I; Ng, C. F.; Grande, E.; Kwon, T. G.; Linke, R.; Lee, J-L; Rosbrook, B.; Thakur, M. N.; Eto, M.; Gross-Goupil, M.
errShare
errSave
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
err2021-05-01
err39
errOAAI
errArmstrong, Andrew J.; Shore, Neal D.; Szmulewitz, Russell Z.; Petrylak, Daniel P.; Holzbeierlein, Jeffrey; Villers, Arnauld; Azad, Arun; Alcaraz, Antonio; Alekseev, Boris; Iguchi, Taro; Gomez-Veiga, Francisco; Rosbrook, Brad; Lee, Ho-Jin; Haas, Gabriel P.; Stenzl, Arnulf
errShare
errSave
Updated Efficacy and Safety Outcomes for Patients with Well-Differentiated Pancreatic Neuroendocrine Tumors Treated with Sunitinib
err2021-01-07
err20
errOAAI
errFazio, Nicola; Kulke, Matthew; Rosbrook, Brad; Fernandez, Kathrine; Raymond, Eric
errShare
errSave
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial
err2020-09-01
err98
errOAAI
errArmstrong, Andrew J.; Lin, Ping; Tombal, Bertrand; Saad, Fred; Higano, Celestia S.; Joshua, Anthony M.; Parli, Teresa; Rosbrook, Brad; van Os, Steve; Beer, Tomasz M.
errShare
errSave
ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
err2020-09-01
err0
errOAAI
errAlcaraz, A.; Szmulewitz, R. Z.; Shore, N.; Crawford, E. D.; Petrylak, D. P.; Holzbeierlein, J.; Villers, A.; Azad, A. A.; Alekseev, B.; Iguchi, T.; Gomez-Veiga, F.; Rosbrook, B.; Sugg, J.; Haas, G. P.; Stenzl, A.; Armstrong, A. J.
errShare
errSave
Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
err2019-07-01
err0
PREAI
errAtkins, Michael; Martini, Jean-Francois; Plimack, Elizabeth; McDermott, David; Puzanov, Igor; Fishman, Mayer; Cho, Daniel; Vaishampayan, Ulka; Rosbrook, Brad; Fernandez, Kathrine; Tarazi, Jamal; George, Saby; Choueiri, Toni
errShare
errSave
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors
err2019-05-14
err8
errOAAI
errFazio, Nicola; Martini, Jean-Francois; Croitoru, Adina E.; Schenker, Michael; Li, Sherry; Rosbrook, Brad; Fernandez, Kathrine; Tomasek, Jiri; Thiis-Evensen, Espen; Kulke, Matthew; Raymond, Eric
errShare
errSave
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data
err2019-01-31
err19
errOAAI
errValle, Juan W.; Borbath, Ivan; Rosbrook, Brad; Fernandez, Kathrine; Raymond, Eric
errShare
errSave
Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial
err2018-12-01
err191
errOAAI
errGross-Goupil, M.; Kwon, T. G.; Eto, M.; Ye, D.; Miyake, H.; Seo, S. I.; Byun, S-S; Lee, J. L.; Master, V.; Jin, J.; DeBenedetto, R.; Linke, R.; Casey, M.; Rosbrook, B.; Lechuga, M.; Valota, O.; Grande, E.; Quinn, D. I.
errShare
errSave
First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data
err2018-07-30
err9
PREAI
errSheng, Xinan; Bi, Feng; Ren, Xiubao; Cheng, Ying; Wang, Jinwan; Rosbrook, Brad; Jiang, Ming; Guo, Jun
errShare
errSave
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours
err2018-07-10
err38
PREAI
errRaymond, Eric; Kulke, Matthew H.; Qin, Shukui; Yu, Xianjun; Schenker, Michael; Cubillo, Antonio; Lou, Wenhui; Tomasek, Jiri; Thiis-Evensen, Espen; Xu, Jian-Ming; Croitoru, Adina E.; Khasraw, Mustafa; Sedlackova, Eva; Borbath, Ivan; Ruff, Paul; Oberstein, Paul E.; Ito, Tetsuhide; Jia, Liqun; Hammel, Pascal; Shen, Lin; Shrikhande, Shailesh V.; Shen, Yali; Sufliarsky, Jozef; Khan, Gazala N.; Morizane, Chigusa; Galdy, Salvatore; Khosravan, Reza; Fernandez, Kathrine C.; Rosbrook, Brad; Fazio, Nicola
errShare
errSave